Pulmonary hypertension imaging

Katz J, Whang J, Boxt LM, et al. Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. JAm Coll Cardiol 1993 21 1475-81. 

Blyth KG, Groenning BA, Martin TN, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J 2005 26 1993-9. 

Wever-Pinzon O, Suma V, Ahuja A, Romero J, Sareen N, Henry SA, et al. Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension a multi-center study. Eur heart J Cardiovasc Imaging October 2012 13(10) 857-62. 

FIGURE 8.5 Proapoprotic experimental therapies in pulmonary arterial hypertension (PAH). A common denominator of these therapies is the induction of apoptosis as well as suppression of proliferation in the pulmonary artery wall. On the left are untreated rats with monocrotaline-induced PAH and on the right are rats treated with elastase inhibitors. Increased apoptosis of the intima-media is showed by TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling), and decreased proliferation is imaged by staining for proliferation cell nuclear antigen (PCNA). The same pattern has been shown in the media of treated rats by all the therapies shown in the box. (From Ref. 116, with permission.)... 

Frank H, Globints S, Glogar D, et al. Detection and quantification of pulmonary artery hypertension with MR imaging results in 23 patients. Am J Roentgenol 1993 161 27-31. 

Benza R, Biederman R, Murali S, et al. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008 52 1683-92. 

Ng CS, Wells AU, Padley SP. A CT sign of chronic pulmonary arterial hypertension the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging 1999 14(4) 270-278. 

---